Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery
Nadine Wafik Nabih, Hatem A. F. M. Hassan, Eduard Preis, Jens Schaefer, Asaad Babker, Anass M. Abbas, Muhammad Amin, Udo Bakowsky, Sherif Ashraf Fahmy
Abstract
performance, and the critical trade-offs between targeting specificity and endosomal escape efficiency. Epidemiological data underscore the pressing need for such innovations, particularly in aggressive and hard-to-treat cancers. While promising, clinical translation remains hindered by challenges in scalable manufacturing, regulatory approval, and biological complexity. Continued interdisciplinary research is essential to transform antibody-functionalized LBNCs from experimental strategies into clinically viable solutions for next-generation, RNA-based cancer therapies.
Topics & Concepts
NanocarriersCancerGenetic enhancementMultiple drug resistanceCancer therapyMedicineGene deliveryDrug resistanceCancer researchPharmacologyGeneChemistryBiologyDrugInternal medicineBiochemistryMicrobiologyRNA Interference and Gene DeliveryAdvanced biosensing and bioanalysis techniquesNanoparticle-Based Drug Delivery